IT1270123B - Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia - Google Patents

Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Info

Publication number
IT1270123B
IT1270123B ITMI942025A ITMI942025A IT1270123B IT 1270123 B IT1270123 B IT 1270123B IT MI942025 A ITMI942025 A IT MI942025A IT MI942025 A ITMI942025 A IT MI942025A IT 1270123 B IT1270123 B IT 1270123B
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
therapy
compositions containing
containing engineered
engineered microorganisms
Prior art date
Application number
ITMI942025A
Other languages
English (en)
Inventor
Aldo Tagliabue
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Priority to ITMI942025A priority Critical patent/IT1270123B/it
Publication of ITMI942025A0 publication Critical patent/ITMI942025A0/it
Priority to AU37453/95A priority patent/AU3745395A/en
Priority to JP8512318A priority patent/JPH10506791A/ja
Priority to PCT/EP1995/003921 priority patent/WO1996011277A1/en
Priority to CA002201721A priority patent/CA2201721A1/en
Priority to EP95935431A priority patent/EP0784689A1/en
Publication of ITMI942025A1 publication Critical patent/ITMI942025A1/it
Application granted granted Critical
Publication of IT1270123B publication Critical patent/IT1270123B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Vengono descritte composizioni farmaceutiche per la somministrazione locale di proteine ricombinanti farmacologicamente attive, contenenti ceppi batterici ingegnerizzati, capaci di colonizzare le superfici mucosali e di produrre localmente la proteina ricombinante di interesse. Si prevede la possibilità di usare batteri con diverse capacità di colonizzazione per la somministrazione localizzata di entità farmacologicamente attive in diversi siti anatomici.
ITMI942025A 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia IT1270123B (it)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
AU37453/95A AU3745395A (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
JP8512318A JPH10506791A (ja) 1994-10-05 1995-10-04 治療用送達系としての微生物
PCT/EP1995/003921 WO1996011277A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
CA002201721A CA2201721A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems
EP95935431A EP0784689A1 (en) 1994-10-05 1995-10-04 Microorganisms as therapeutic delivery systems

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Publications (3)

Publication Number Publication Date
ITMI942025A0 ITMI942025A0 (it) 1994-10-05
ITMI942025A1 ITMI942025A1 (it) 1996-04-05
IT1270123B true IT1270123B (it) 1997-04-28

Family

ID=11369649

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI942025A IT1270123B (it) 1994-10-05 1994-10-05 Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia

Country Status (6)

Country Link
EP (1) EP0784689A1 (it)
JP (1) JPH10506791A (it)
AU (1) AU3745395A (it)
CA (1) CA2201721A1 (it)
IT (1) IT1270123B (it)
WO (1) WO1996011277A1 (it)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
EP1012232B1 (en) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AU770726B2 (en) * 1998-10-20 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of a cytokine-producing lactococcus strain to treat colitis
FR2791998B1 (fr) * 1999-04-07 2001-06-08 Agronomique Inst Nat Rech Lactocoques modifies exprimant une catalase et leurs utilisations
DK1739178T3 (da) * 1999-07-05 2010-11-22 Actogenix Nv Levering af trekløverpeptider
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
US7569218B2 (en) * 2000-07-27 2009-08-04 The Trustees Of The University Of Pennsylvania Compositions for and methods of using herpes simplex virus glycoprotein D to suppress immune responses
CA2342040C (en) 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
CN1646020A (zh) * 2002-01-31 2005-07-27 圣必健公司 将核酸和/或蛋白质导入呼吸系统的方法与制剂
AU2003276822A1 (en) 2002-03-08 2004-02-02 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
CA2489930A1 (en) 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
EP1590443A4 (en) 2003-01-29 2009-01-07 Osel Inc SURFACE EXPRESSION OF BIOLOGICALLY ACTIVE PROTEINS IN BACTERIA
ATE511848T1 (de) 2004-08-25 2011-06-15 Us Gov Health & Human Serv Lebendige mikrobielle mikrobizide
EP1790332B1 (en) 2004-09-10 2010-07-21 Asahi Glass Company, Limited Human papilloma virus vaccine for oral administration
US7456011B2 (en) 2005-01-12 2008-11-25 Osel, Inc. Modified cyanovirin-n polypeptide
PT2119450E (pt) 2005-11-29 2013-04-26 Actogenix Nv Indução de tolerância da mucosa a autoantigénios de células beta de ilhéus pancreáticos
WO2007128757A2 (en) * 2006-05-02 2007-11-15 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
RU2495129C2 (ru) 2007-01-12 2013-10-10 Актогеникс Н.В. ПРОМОТОРЫ Lactococcus И ИХ ПРИМЕНЕНИЕ:
EP2125010B1 (en) 2007-01-25 2014-06-04 Actogenix N.V. Treatment of immune disease by mucosal delivery of antigens using genetically modified lactobacillus
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
CN102414310B (zh) 2009-04-30 2015-05-06 阿克图杰尼斯公司 用于冷冻干燥乳酸菌的冷冻保护剂
WO2011039137A1 (en) 2009-09-29 2011-04-07 Actogenix N.V. Lactobacillus and streptococcus promoters and uses thereof
ES2613755T3 (es) 2010-01-14 2017-05-25 Inserm - Institut National De La Santé Et De La Recherche Médicale Bacteria probiótica recombinante para la prevención y tratamiento de la Enfermedad Inflamatoria Intestinal (EII) y del Síndrome del Intestino Irritable (SII)
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
FR2960001A1 (fr) * 2010-05-12 2011-11-18 Univ Rennes Vecteur recombinant pour la production et la secretion de sequences d'acides amines d'interet par les bacteries propioniques et ses applications
US9476056B2 (en) 2010-05-12 2016-10-25 Universite De Rennes 1 Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof
CA2802994A1 (en) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
CN101921725B (zh) * 2010-07-27 2013-06-05 浙江大学 一种口服免疫阻断鸡生长抑素作用的转化子及其应用
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
EP2758513B1 (en) 2011-09-23 2018-05-16 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2014025938A1 (en) 2012-08-07 2014-02-13 TopGeniX, Inc. Topical composition comprising transformed bacteria expressing a compound of interest
JP2017519823A (ja) 2014-06-17 2017-07-20 トップジェニックス, インク.Topgenix, Inc. Ｕｖ保護用局所製剤
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
SG11202109537WA (en) 2019-03-04 2021-09-29 Celloryx AG Chloride-inducible prokaryotic expression system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1321962C (en) * 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations

Also Published As

Publication number Publication date
CA2201721A1 (en) 1996-04-18
AU3745395A (en) 1996-05-02
EP0784689A1 (en) 1997-07-23
JPH10506791A (ja) 1998-07-07
ITMI942025A0 (it) 1994-10-05
WO1996011277A1 (en) 1996-04-18
ITMI942025A1 (it) 1996-04-05

Similar Documents

Publication Publication Date Title
IT1270123B (it) Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
FI964681A (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
WO1998007745A3 (en) Compositions and methods for treating infections using analogues of indolicidin
AU6604798A (en) Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
AU2845599A (en) Pharmaceutical compositions and their use
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
MXPA03001673A (es) Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas.
IL156942A0 (en) Compounds, pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
AU2000255628A1 (en) Formulation comprising thymol useful in the treatment of drug resistant bacterial infections
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
AU1384995A (en) Human circulating cytokine cc-1
ITMI950378A0 (it) Associazioni di fermenti lattici e lisati di saccaromiceti loro uso terapeutico e composizioni che le contengono
AU2001267561A1 (en) Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined withspecific pharmaceutical active agents
ZA97596B (en) Solid instant-release forms of administration and processes for their production
MY138219A (en) Biologically active peptides
AUPN907296A0 (en) Biocontrol agents for use in treatment of opportunistic infections
WO1998024482A3 (de) Verwendung von endothelin-konjugaten in der therapie, neue endothelin-konjugate, diese enthaltende mittel, sowie verfahren zu deren herstellung
IT1252160B (it) Composizioni farmaceutiche contenenti il peptidoglicano del lactobacillus casei
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
WO1998050397A3 (de) Chimäre oligonucleotide und ihre verwendung
WO2003025005A3 (en) Purified bacterial polypeptides involved in protein processing
ITMI961647A1 (it) Uso di particolari specie di batteri lattici o loro miscele per l'autopurificazione fisiologica della vagina e composizioni farmaceutiche che le contengono.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971029